Chard R L, Finklestein J Z, Sonley M J, Nesbit M, McCreadie S, Weiner J, Sather H, Hammond G D
Med Pediatr Oncol. 1978;4(3):263-73. doi: 10.1002/mpo.2950040310.
One hundred-sixty-three children with acute nonlymphocytic leukemia (ANLL) were treated with a multiple-drug induction program (PATCO) consisting of prednisone (PDN), cytosine arabinoside ((Ara-C), 6-thioguanine (6-TG), cyclophosphamide (CPM), and Oncovin (VCR). Ninety-six, 59%, obtained a remission. Remission was maintained with daily 6-TG and four-day pulses of Ara-C and CPM with a single dose of VCR every 28 days. The median duration of remission was 11.5 months. Certain prognostic factors affected induction rate and remission duration. Initial white blood count (WBC) was a significant factor in achieving a remission, whereas age, sex, and type of ANLL had no effect. Initial WBC, age, and sex had a significant effect on remission duration, but type of ANLL had no effect. Relapsing patients were treated with daunomycin and 5-azacytidine. The reinduction rate was 53% with a median second remission duration of 190 days. Overall survival for the 163 patients is 55.4% at 12 months, 31.5% at 24 months, 21.4% at 36 months, and 19% at 48 months.
163名急性非淋巴细胞白血病（ANLL）患儿接受了一个多药诱导方案（PATCO）治疗，该方案包括泼尼松（PDN）、阿糖胞苷（Ara-C）、6-硫鸟嘌呤（6-TG）、环磷酰胺（CPM）和长春新碱（VCR）。96名患儿（59%）获得缓解。缓解期通过每日服用6-TG以及每28天进行一次为期4天的阿糖胞苷和环磷酰胺脉冲治疗，并单次注射长春新碱来维持。缓解期的中位持续时间为11.5个月。某些预后因素影响诱导率和缓解期持续时间。初始白细胞计数（WBC）是实现缓解的一个重要因素，而年龄、性别和ANLL类型则无影响。初始白细胞计数、年龄和性别对缓解期持续时间有显著影响，但ANLL类型无影响。复发患者接受柔红霉素和5-氮杂胞苷治疗。再诱导率为53%，第二次缓解期的中位持续时间为190天。163名患者的12个月总生存率为55.4%，24个月为31.5%，36个月为21.4%，48个月为19%。
